title: A case study of personalized therapy for osteosarcoma.
abstract: BACKGROUND
  Effective targeted therapies are needed in sarcomas, but the biological heterogeneity of these tumors has presented a challenge to clinical integration of small molecule inhibitors in sarcoma treatment. Here we outline a process to personalize therapy for sarcomas through a case study of a canine with spontaneous osteosarcoma.
  
  
  METHODS
  Rapid establishment of a primary tumor cell culture is described, followed by efficient functional characterization of the tumor that identified the Src inhibitor dasatinib as the most effective targeted therapy for this individual dog.
  
  
  RESULTS
  Adjuvant dasatinib was administered for a total of 26 weeks following treatment with chemotherapy. Pharmacokinetic studies confirm that a therapeutic serum concentration was achieved at a tolerable dose of 0.75 mg/kg/day. The canine patient remains without evidence of recurrent disease 24 months following initial diagnosis.
  
  
  CONCLUSIONS
  The approach described through this illustrative case study is broadly applicable and might be used for other solid tumors in canines as well as in humans.
authors.affiliation: Pediatric Cancer Biology Program, Papé Family Pediatric Research Institute, Oregon Health & Sciences University, Portland, Oregon 80523-1620, USA.
authors.forename: Lara E
authors.initials: LE
authors.lastname: Davis
authors.forename: Nicolle E
authors.initials: NE
authors.lastname: Hofmann
authors.forename: Guangheng
authors.initials: G
authors.lastname: Li
authors.forename: Elaine T
authors.initials: ET
authors.lastname: Huang
authors.forename: Marc M
authors.initials: MM
authors.lastname: Loriaux
authors.forename: Shay
authors.initials: S
authors.lastname: Bracha
authors.forename: Stuart C
authors.initials: SC
authors.lastname: Helfand
authors.forename: John E
authors.initials: JE
authors.lastname: Mata
authors.forename: Kevin
authors.initials: K
authors.lastname: Marley
authors.forename: Atiya
authors.initials: A
authors.lastname: Mansoor
authors.forename: Jeffrey W
authors.initials: JW
authors.lastname: Tyner
authors.forename: Jinu
authors.initials: J
authors.lastname: Abraham
authors.forename: Bernard
authors.initials: B
authors.lastname: Séguin
authors.forename: Charles
authors.initials: C
authors.lastname: Keller
mesh_terms: D000818:Animals; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000662:veterinary; D045744:Cell Line, Tumor; D000069439:Dasatinib; D004283:Dog Diseases / Q000000981:diagnostic imaging / Q000188:drug therapy*; D004285:Dogs; D012516:Osteosarcoma / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000662:veterinary; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics; D011743:Pyrimidines / Q000008:administration & dosage / Q000493:pharmacokinetics; D011859:Radiography; D013844:Thiazoles / Q000008:administration & dosage / Q000493:pharmacokinetics; D013997:Time Factors; D019061:src-Family Kinases / Q000037:antagonists & inhibitors
chemical_list: D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D019061:src-Family Kinases; D000069439:Dasatinib